Lantern Pharma (LTRN) Income from Continuing Operations (2020 - 2026)
Lantern Pharma's (LTRN) quarterly Income from Continuing Operations came in at 3383087.0 in Q1 2026, up 27.68% YoY from 2649564.34 in Q1 2025, and up 18.93% on a QoQ basis from 4173287.0 in Q4 2025.
Lantern Pharma (LTRN) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Lantern Pharma (LTRN) has 7 years of Income from Continuing Operations data on file, last reported at 3383087.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 27.68% year-over-year to 3383087.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 17903170.0 (up 14.47% YoY) and the FY2025 annual result came in at 39294991.0, changed 0.12% from the prior year.
- Income from Continuing Operations advanced to 3383087.0 in Q1 2026, from 4173287.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 2821137.0 in Q3 2022 to a low of 6149883.0 in Q4 2022.
- A 5-year average of 4755789.12 and a median of 4630995.0 in 2023 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 31.61% in 2022, down 81.69% in 2022.
- Tracing LTRN's Income from Continuing Operations over 5 years: stood at 6149883.0 in 2022, then advanced by 24.7% to 4630995.0 in 2023, then declined by 25.01% to 5789006.0 in 2024, then climbed by 27.91% to 4173287.0 in 2025, then rose by 18.93% to 3383087.0 in 2026.
- The last three Income from Continuing Operations figures came in at 3383087.0 (Q1 2026), 4173287.0 (Q4 2025), and 5802879.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Lantern Pharma | 26.05 Mn | 26.05 Mn | - | -3.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.38 Mn |
| Dec 31, 2025 | -4.17 Mn |
| Sep 30, 2025 | -5.80 Mn |
| Jun 30, 2025 | -4.54 Mn |
| Mar 31, 2025 | -4.68 Mn |
| Dec 31, 2024 | -5.79 Mn |
| Sep 30, 2024 | -5.01 Mn |
| Jun 30, 2024 | -5.45 Mn |
| Mar 31, 2024 | -5.58 Mn |
| Dec 31, 2023 | -4.63 Mn |
| Sep 30, 2023 | -4.09 Mn |
| Jun 30, 2023 | -5.94 Mn |
| Mar 31, 2023 | -4.19 Mn |
| Dec 31, 2022 | -6.15 Mn |
| Sep 30, 2022 | -2.82 Mn |
| Jun 30, 2022 | -4.51 Mn |
| Mar 31, 2022 | -4.10 Mn |
| Dec 31, 2021 | -7.06 Mn |
| Sep 30, 2021 | -4.13 Mn |
| Jun 30, 2021 | -2.48 Mn |